241 related articles for article (PubMed ID: 9155516)
61. Prostate cancer: a review of common underwriting problems, Part 1.
Richie RC; Swanson JO
J Insur Med; 2004; 36(3):242-54. PubMed ID: 15495440
[TBL] [Abstract][Full Text] [Related]
62. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
[TBL] [Abstract][Full Text] [Related]
63. Solving the overdiagnosis dilemma.
Esserman L; Thompson I
J Natl Cancer Inst; 2010 May; 102(9):582-3. PubMed ID: 20413743
[No Abstract] [Full Text] [Related]
64. [Screening with PSA (Prostate Specific Antigen) raises ethical questions].
Taube A
Lakartidningen; 1996 Sep; 93(39):3341. PubMed ID: 8926796
[No Abstract] [Full Text] [Related]
65. Prostate cancer screening with PSA: "Aequanimitas".
Sadi MV
Int Braz J Urol; 2013; 39(4):447-53. PubMed ID: 24054394
[No Abstract] [Full Text] [Related]
66. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
67. [Evaluation of mass screening for prostatic cancer].
Nakagawa S
Nihon Rinsho; 2002 Dec; 60 Suppl 11():289-93. PubMed ID: 12599587
[No Abstract] [Full Text] [Related]
68. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
D'Amico AV
J Clin Oncol; 2008 Feb; 26(6):823-4. PubMed ID: 18281649
[No Abstract] [Full Text] [Related]
69. Prostate carcinoma: clarification through clinical insight and molecular diagnostics.
Meyers FJ; DeVere White RW
West J Med; 1998 Jun; 168(6):525. PubMed ID: 9655997
[No Abstract] [Full Text] [Related]
70. Should men be screened for prostate cancer?
Patel SM
N C Med J; 1999; 60(5):275-7. PubMed ID: 10495656
[No Abstract] [Full Text] [Related]
71. Editorial comment: factor that influence serum prostate-specific antigen levels in terms of maintaining quality within a PSA screening system.
Ito K
Eur Urol; 2007 Sep; 52(3):714. PubMed ID: 17849514
[No Abstract] [Full Text] [Related]
72. What's new in prostate cancer screening and prevention?
Klein EA
Cleve Clin J Med; 2009 Aug; 76(8):439-45. PubMed ID: 19652036
[TBL] [Abstract][Full Text] [Related]
73. [Prostatic cancer--can unnecessary therapy be avoided? Prostate-specific antigens (PSA) kinetics can guide the management].
Malmström PU
Lakartidningen; 2006 Feb 1-7; 103(5):279. PubMed ID: 16512565
[No Abstract] [Full Text] [Related]
74. New Zealand should introduce population screening for prostate cancer using PSA testing: yes.
Smart R
J Prim Health Care; 2009 Dec; 1(4):319-20. PubMed ID: 20690342
[No Abstract] [Full Text] [Related]
75. [Screening for asymptomatic prostate cancer].
Sappino AP
Rev Med Suisse; 2006 May; 2(66):1326-7, 1329-30. PubMed ID: 16775993
[TBL] [Abstract][Full Text] [Related]
76. [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer].
Nutahara K; Higashihara E
Rinsho Byori; 2001 Oct; 49(10):963-6. PubMed ID: 11769472
[TBL] [Abstract][Full Text] [Related]
77. States renewing attention to prostate cancer.
Rossiter C
NCSL Legisbrief; 2012 Sep; 20(36):1-2. PubMed ID: 23072022
[No Abstract] [Full Text] [Related]
78. Does early detection of prostate cancer offer more good than harm?
Feightner JW
Can J Oncol; 1994 Nov; 4 Suppl 1():74-5. PubMed ID: 8853495
[No Abstract] [Full Text] [Related]
79. Early detection of prostate cancer.
Taneja SS
Urol Clin North Am; 2014 May; 41(2):xi-xii. PubMed ID: 24725495
[No Abstract] [Full Text] [Related]
80. Screening for prostate cancer: conceptual considerations.
Meyer F
Can J Oncol; 1994 Nov; 4 Suppl 1():72-3. PubMed ID: 8853494
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
